期刊文献+

71例自身免疫性肝病自身抗体检测回顾性分析 被引量:5

A retrospective analysis of the detection of autoantibodies of 71 cases of autoimmune liver disease
原文传递
导出
摘要 目的探讨自身免疫性肝病自身抗体的检测及临床应用价值。方法采用间接免疫荧光法、免疫印迹法检测自身免疫性肝病(AIH、PBC、PSC)患者血清中出现的ANA、ASMA、AMA抗体,并对AMA-M2亚型、抗SLP/LP、抗LKM-1、抗LC-1肝病自身抗体进行检测。结果自身免疫性肝病患者抗核抗体的阳性率为61.97%,抗体的滴度水平>1∶100,在抗核抗体的荧光模型中,AIH主要以颗粒型、均质型为主,PBC主要以核膜型、着丝点型为主。在AIH中,抗SLP/LP、抗LKM-1、抗LC-1、AMA-M2的检出率分别为16.67%、12.50%、4.17%、4.17%。结论利用对自身免疫性肝病自身抗体的检测,有助于帮助诊断和鉴别不明原因的肝脏疾病,提高对自身免疫性肝病的诊断和治疗。 Objective To investigate the detection and clinical application value of autoantibodies in autoimmune liver disease.Methods Using indirect immunofluorescence and immunoblotting to detect ANA,ASMA,AMA antibody in serum of patients with autoimmune hepatitis( AIH,PBC and PSC) and autoantibodies of the subtype AMA- M2,anti SLP / LP,anti LKM- 1,anti LC- 1 were detected. Results The anti nuclear antibodies in patients with autoimmune liver disease positive rate was61. 97%,and the antibody titer levels was above 1∶100; in the fluorescence model of anti nuclear antibody,AIH mainly was in particle type,homogeneous type; PBC was mainly in the nuclear membrane,centromere type. In AIH,the detection rate of anti SLP / LP,anti LKM- 1,anti LC- 1 and AMA- M2 was respectively 16. 67%,12. 50%,4. 17%,4. 17%. Conclusion Dectecting the autoantibodies in autoimmune liver disease can help to diagnose,identify the cause of liver disease,improve the diagnosis and treatment of autoimmune liver disease.
出处 《中国卫生检验杂志》 CAS 2015年第15期2590-2591,2598,共3页 Chinese Journal of Health Laboratory Technology
关键词 自身免疫性肝病 自身抗体 免疫印迹法 Autoimmune liver diseases Autoantibodies Immunoblotting
  • 相关文献

参考文献6

二级参考文献69

  • 1姚根宏,侯亚义.雌激素调节免疫系统的研究进展[J].卫生研究,2004,33(6):759-761. 被引量:7
  • 2Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.Hepatology, 2000, 31: 1005-1013.
  • 3Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmane hepatitis. J Hepatol, 1999, 31: 929-938.
  • 4Leung PS, Van de Water J, Coppel RL, et al. Molecular aspects and the pathological basis of primary biliary cirrhosis. J Autoimmun,1996, 9: 119-128.
  • 5Metcalf JV, Mitchison HC, Palmer JM, et al. Natural history of early primary biliary cirrhosis. Lancet, 1996,348: 1399-1402.
  • 6Thomsen BL, Sorensen TI. Analysis of the treatment effect on recurrent bleeding and death in patients with cirrhosis and esophageal varices: multistage competing-risks model compared to conventional methods. J Hepatol, 1998, 28: 107-114.
  • 7Iknuo N, Mackay IR, Jois J, et al. Antimitochondrial autoantibodies in saliva and sera from patients with primary biliary cirrhosis [J]. J Gastroenterol Hepatol, 2001, 16 ( 5 ) :1390-1394.
  • 8Muratori P,Muratori L,Ferrari R, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis[J]. Am J Gastroenterol, 2003,98 (2) : 431-437.
  • 9Worman H J, Courvalin JC. Antinuclear antibodies specific for primary biliary cirrhosis [J]. Autoimmune Rev, 2003, 2 (3) :211-217.
  • 10Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases Practice Guidelines Committee [J]. Hepatology, 2000, 31 ( 4 ), 1005-1013.

共引文献108

同被引文献46

引证文献5

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部